Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Study Summary

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.

Conditions

Prostate Cancer

Interventions / Drugs

AMG 509 Abiraterone Enzalutamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment479 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.158185+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.